.. Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension Actavis plc today confirmed that the business has received a complete response letter from the U.S. Food and Drug Administration for its New Drug Software for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension. Although we are disappointed in the receipt of a full response letter, Actavis remains committed to bringing treatments to advertise that address the significant general public health issue of cardiovascular disease, stated David Nicholson, Senior Vice President, Actavis Global Brands R&D.The data provide good evidence that APC-300 gets the potential to decrease the AR transcriptional activity of ADPC and CRPC cells by blocking the AR occupancy on AR-responsive elements in target genes. The data also show that APC-300 had a substantial effect on reducing the development of ADPC and CRPC and reducing the levels of PSA in the mouse tumor model. Taken together, these data claim that APC-300 may very well play a significant role in the treatment of prostate cancer. Dennis J. Carlo, Ph.D., CEO and President of Adamis, claims that, ‘We continue to build upon our prostate tumor franchise. New independent released data validate the need for our three substances for the treating prostate and pancreatic tumor. We will continue steadily to concentrate and aggressively move these compounds into the clinic.